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Background:  Intravenous  nicorandil  infusion  dilates  the  coronary  artery  and  reduces  inﬂammation,  coro-
nary  spasm,  and  arrhythmia.  Periprocedural  myocardial  infarction  (PMI)  is  a frequent  and  prognostically
important  complication  of  percutaneous  coronary  intervention  (PCI).  This  prospective  randomized  study
was  designed  to  evaluate  the  efﬁcacy  of  intracoronary  nicorandil  on  PMI  after  elective  PCI.
Methods and results:  Eighty-one  patients  with  stable  or unstable  angina  undergoing  PCIs  of  the  left  anterior
descending  artery  were  randomly  assigned  to the  nicorandil  group  (n =  41)  or the  control  group (n =  40).
In  the  nicorandil  group,  4 mg  of  intracoronary  nicorandil  was  infused  prior  to  PCI. Post-PCI,  peak  levels
of  creatine  kinase  (CK)-MB  and troponin  I  were  measured  and  angiographic  ﬁndings  were  analyzed.  Side
branch  status  was  also  assessed.  All PCIs  were  successful.  One  cerebrovascular  infarction  and  one acute  ST
segment  elevation  myocardial  infarction  with  acute  stent  thrombosis  occurred  in  the  nicorandil  group.  Nooronary  disease deaths  occurred,  and  no other  major  cardiac  adverse  events  were  observed  in either  group  over  6 months
follow-up.  The  post-PCI  peak  CK-MB  and  troponin  I levels  were  not  signiﬁcantly  different  between  the
two  groups.  There  were  no signiﬁcant  differences  between  the  nicorandil  and  control  subjects  in  side
branch  occlusion  or ﬂow  reduction,  or in the  jail index.
Conclusions: Intra-coronary  nicorandil  infusion  had  no  signiﬁcant  effect  on PMI  and  cardiac  enzymes  after
PCI  in  patients  with  stable  or unstable  angina.
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ntroduction
Periprocedural myocardial infarction (PMI) is a common com-
lication of percutaneous coronary intervention (PCI). PMI  is
elated to myocardial damage after PCI and is associated with worse
ubsequent cardiac outcomes [1]. It occurs most commonly due
o distal embolization, side-branch occlusion, coronary dissection,
nd altered collateral ﬂow [2]. Given its undesirability, a num-
er of therapeutic modalities to reduce PMI  have been considered,
ut no practical and useful method has yet been clearly demon-
trated. Nicorandil is an antianginal agent with a dual mechanism
f action; it induces nitrate- and ATP-sensitive potassium chan-
els to open. The action of nicorandil on nitrate-mediated channels
auses vasodilation of systemic veins and epicardial coronary arter-
es. The opening of ATP-sensitive potassium channels in response
∗ Corresponding author at: Division of Cardiology, Department of Internal
edicine,  Pusan National University Hospital, 305 Gudeok-Ro, Seo-Gu, Busan 602-
39, Republic of Korea. Tel.: +82 051 240 7794–5; fax: +82 051 240 7796.
E-mail address: glaraone@hanmail.net (H.C. Lee).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.03.017anese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
to nicorandil causes vasodilation of peripheral and coronary resis-
tance arterioles, dilating resistance vessels [3]. Nicorandil also
reduces inﬂammation, arrhythmia, and spasm. Intravenous and
intracoronary nicorandil in acute ST segment elevation myocardial
infarction (STEMI) reduced no reﬂow, slow ﬂow, and infarct area
[3,4]. Murakami et al. reported that intravenous nicorandil infu-
sion reduced the incidence of minor cardiac marker elevation in
patients undergoing elective PCI [5]. However, data on the inﬂuence
of intracoronary nicorandil on the prevention of PMI  are limited.
We therefore conducted a prospective, randomized, single-center
study that was  designed to evaluate the efﬁcacy of intra-coronary
nicorandil on PMI  prevention.
Methods
SubjectsThe  study group comprised 81 patients who  visited the Car-
diology Department of Pusan National University Hospital for
chest pain between March 2010 and June 2011. All subjects were
vier Ltd. All rights reserved.
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sel disease (nicorandil group, 17/41 (41.5%); control group, 17/40
(42.5%), p = 0.265) (Table 2). Mean LAD artery lesion diameters were
2.4 ± 0.51 mm in the nicorandil group and 2.43 ± 0.51 mm in the
control group. LAD artery lesion lengths were 27.4 ± 3.9 mm in the
Table 1
Baseline clinical characteristics.
N (90) Nicorandil
group (N = 41)
Control group
(N  = 40)
p
Disease
Stable angina 21 (51.2%) 23 (57.5%) 0.657
Unstable angina 20 (48.8%) 17 (42.5%)
Age (years) 66.2 ± 9 65.3 ± 10 0.654
Male 20 (48.8%) 25 (62.5%) 0.266
Hypertension 27 (65.9%) 27 (67.5%) 0.531
Diabetes mellitus 15 (36.6%) 14 (35.0%) 0.533
Smoking 14 (34.1%) 14 (35.0%) 0.561
Family history of MI  7 (17.1%) 5 (12.5%) 0.753
Previous angioplasty 3 (7.3%) 0 (0%) 0.241
Dyslipidemia 9 (22.0%) 8 (20.0%) 0.5238 J. Hwang et al. / Journal o
iagnosed with stable or unstable angina pectoris, without baseline
levation of cardiac enzymes. Exclusion criteria were acute STEMI,
on-ST segment elevation myocardial infarction (NSTEMI), liver
nd kidney dysfunction, age > 80 years, cardiogenic shock, tempo-
ary pacemakers or intra-aortic balloon pumps, and use of nitrate,
icorandil, or calcium channel blockers before PCI. The patients
ere scheduled to undergo PCI at the left anterior descending (LAD)
rtery. For evaluating side branch occlusion, cases in which stent
nsertion into side branches was required were also excluded. Sub-
ects were assigned to a nicorandil group (n = 41) or a control group
n = 40). In the nicorandil group, 4 mg  of intra-coronary nicorandil
as infused prior to PCI (2 mg  before ballooning and 2 mg  before
tenting). The control group was treated without nicorandil. The
tudy protocol was approved by the ethical committee of Pusan
ational University Hospital and written informed consent was
btained from each patient.
rocedures
Diagnostic  coronary angiographies were performed via the right
r left femoral artery and via the radial artery using the Seldinger
ethod. All patients received antiplatelet agents (aspirin, clopid-
rel) and heparin. The guidewire was passed into the culprit lesion.
atients in the nicorandil group were then administered 2 mg  intra-
oronary nicorandil prior to percutaneous transluminal coronary
ngioplasty. An additional dose of 2 mg  intracoronary nicorandil
as given before stent implantation. A minimum interval of 3 min
as observed between the ﬁrst and second doses of nicorandil,
o reduce adverse effects. In the control group, conventional PCI
as performed without nicorandil administration. In the nicorandil
ecipients and the control subjects, one or more drug-eluting stents
DES) were implanted for the treatment of LAD artery lesions. Suc-
ess of the procedure was deﬁned as >50% increase in internal
uminal diameter, <30% residual stenosis, and a thrombolysis in
yocardial infarction (TIMI) ﬂow grade 3.
ardiac enzymes
Blood  was collected just before PCI and 6, 12, 24, 48, and 72 h
fter successful PCI for measuring the concentrations of creatine
inase myocardial band (CK-MB) and cardiac troponin I (cTnI). CK-
B and cTnI were measured by immunoassay (UniCel DxI 800
ystem, Beckman Coulter, Fullerton, CA, USA). The normal refer-
nce values for CK-MB, and cTnI were <5 g/L, and 0.05 ng/mL,
espectively.
nalysis of coronary angiography
Angiograms  were taken after stent implantation in all study
atients, and no-reﬂow phenomenon (transient or ﬁnal), slow ﬂow,
issection, and distal embolization were recorded. One of the main
auses of PMI  is side branch occlusion. Side branches of more than
 mm and less than 2 mm in diameter were therefore analyzed,
ncluding septal branches and diagonal branches. Side branch sta-
us was described in terms of branch occlusion, narrowing, and TIMI
ow reduction. The side branch was considered narrowed when
here was a >50% stenosis after stent placement and reduction of
IMI ﬂow by more than one grade at any time after stent place-
ent was deﬁned as “TIMI ﬂow reduction”. As described above,
jail index” was deﬁned and used. The jail index was calculated
s the number of occluded side branches, or side branches with
 reduced TIMI ﬂow after PCI, divided by the total number of side
ranches of the LAD covered by the stents. Jail index was  expressed
s a percentage.iology 62 (2013) 77–81
Clinical outcomes
Clinical outcomes were evaluated by recording major adverse
cardiac events (MACEs) during the hospitalization period and over 6
months of follow-up. MACEs were deﬁned as death, STEMI, NSTEMI,
target lesion revascularization (TLR), and target vessel revasculari-
zation (TVR). TLR was  deﬁned as a repeat revascularization within
the stent or within segments 5-mm distal or proximal to the stent.
TVR was  deﬁned as a revascularization of any lesion located in the
same previously treated epicardial vessel.
Statistical analysis
Data  are presented as mean ± SD or mean ± SE. For continu-
ous variables, Student’s t test was  used to assess the differences
between groups. Nominal variables were analyzed with the chi-
squared test. A value of p < 0.05 was  considered to be statistically
signiﬁcant.
Results
Patient characteristics
Of  81 patients eligible for this study, 41 were assigned to the
nicorandil group and 40 to the control group. There were no
differences between the nicorandil group and the control group
in background factors including age, sex, hypertension, diabetes
mellitus, dyslipidemia, smoking, previous history of myocardial
infarction (MI) or coronary angioplasty, and family history of
ischemic heart disease. In addition, there were no signiﬁcant differ-
ences between the two  groups in laboratory ﬁndings such as lipid
proﬁle, C-reactive protein (CRP), and creatinine (Table 1).
Coronary  angiographic and procedural characteristics
There were no differences between the nicorandil and control
groups in lesion type according to the American College of Cardi-
ology/American Heart Association lesion classiﬁcation [nicorandil
group: type B2 2/41 (4.9%), type C 39/41 (95.1%); control group:
type B2 1/40 (2.5%), type C 37/40 (92.5%), p = 0.305]. There were also
no differences between the groups in the occurrence of three ves-Total cholesterol (mg/dL) 182.5 ± 31.8 193.9 ± 35.9 0.118
LDL (mg/dL) 118.18 ± 26.3 119.67 ± 34.9 0.835
HDL (mg/dL) 41.15 ± 9.5 43.4 ± 11.64 0.347
Creatinine (mg/dL) 1.02 ± 0.53 1.04 ± 0.23 0.8
hsCRP (mg/dL) 0.788 ± 2.0 0.448 ± 0.5 0.287
MI,  myocardial infarction; LDL, low-density lipoprotein; HDL, high-density lipopro-
tein; hsCRP, high-sensitivity C-reactive protein.
J. Hwang et al. / Journal of Card
Table  2
Angiographic characteristics.
N (90) Nicorandil
group (N = 41)
Control  group
(N  = 40)
p  value
Lesion length (mm) 27.4 ± 3.9 28.4 ± 6.6 0.458
Pre RD (mm)  2.4 ± 0.51 2.43 ± 0.51 0.793
Pre MLD  (mm)  0.68 ± 0.46 0.72 ± 0.37 0.148
Pre %DS 71.7 ± 14.9 72.2 ± 12.6 0.124
Post RD (mm) 2.9 ± 0.47 2.9 ± 0.47 0.925
Post MLD  (mm)  2.4 ± 0.45 2.5 ± 0.35 0.130
Lesion type with ACC/AHA
B2  2 (4.9%) 1 (2.5%) 0.305
C 39 (95.1%) 37 (92.5%)
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vThree  vessel disease 17 (41.5%) 17 (42.5%) 0.265
D, reference diameter; MLD, minimal luminal diameter; DS, diameter stenosis.
icorandil group and 28.4 ± 6.6 mm in the control group. The type
f stents used did not differ between the two groups. All PCI pro-
edures were successful, as deﬁned above.
ost-PCI peak cardiac enzyme and side branch analysis
In  all patients, cardiac enzyme levels just before PCI were within
he normal range. The post-PCI peak CK-MB and troponin I levels
ere not statistically signiﬁcantly different between the nicorandil
nd control groups (CK-MB: 2.51 ± 1.96 g/L nicorandil group,
.85 ± 1.79 g/L controls, p = 0.065; troponin I: 0.53 ± 0.67 ng/mL
icorandil group, 0.34 ± 0.54 ng/mL controls, p = 0.154) (Table 3).
o statistically signiﬁcant differences were observed in the fre-
uency of CK-MB and troponin I level elevation above upper
ormal limits [CK-MB: 3/41 (7.3%) nicorandil group, 2/40 (5.0%)
ontrols, p = 0.52, Troponin-I: 6/41 (14.6%) nicorandil group, 7/40
17.5%) controls, p = 0.480] (Fig. 1). The rate of side branch occlu-
ion after the procedure showed no signiﬁcant difference between
able 3
ost-PCI peak cardiac enzyme and side branch analysis of LAD after PCI.
N (90) Nicorandil
group (N = 41)
Control group
(N  = 40)
p value
Peak CK-MB (g/L) 2.51 ± 1.96 1.85 ± 1.79 0.099
Peak troponin I (ng/mL) 0.53 ± 0.67 0.34 ± 0.56 0.196
Rates of side branch occlusion 5.3% 2% 0.276
Rates of side branch narrowing 21.3% 6% 0.017
Rates of TIMI grade reduction 2.6% 6% 0.292
Jail index (%)a 7.6 ± 2.1 7.3 ± 1.9 0.951
K-MB, creatine kinase-MB; TIMI, thrombolysis in myocardial infarction.
a Jail index (%) = (the numbers of occluded side branches or side branches with a
educed TIMI ﬂow)/(total numbers of side branches on LAD covered by stents) × 100.
ig. 1. Frequency of cardiac enzyme elevation after percutaneous coronary inter-
ention on left anterior descending artery. CK-MB, creatine kinase myocardial band.iology 62 (2013) 77–81 79
groups (5.3% nicorandil group, 2% controls, p = 0.276). The extent
of TIMI ﬂow reduction was also similar between both groups (2.6%
nicorandil group, 6% controls, p = 0.292). However, side branch nar-
rowing was signiﬁcantly more frequent in the nicorandil group
(21.3% nicorandil group, 6% controls, p = 0.017). The jail index was
not signiﬁcantly different between groups at 7.7 ± 2.1% in the
nicorandil subjects and 7.4 ± 1.9% in control patients (p = 0.823)
(Table 3).
Clinical outcomes
Mortality was not observed in either group. Acute STEMI due to
acute stent thrombosis was observed in one case in the nicorandil
group. There was  also one case of in-hospital cerebral infarction
in the nicorandil group. In-hospital clinical outcomes were not
statistically signiﬁcantly different (Table 4). During 6 months of
follow-up, no deaths or further MACEs were observed. No adverse
effects, such as arrhythmia or hypotension, were observed after
administration of intracoronary nicorandil.
Discussion
PCI has become a standard revascularization procedure for
patients with signiﬁcant coronary artery disease (CAD). Remark-
able advances have improved its safety and PCI has a central role
in the management of patients with CAD. PMI  occurs in 5–30% of
patients after PCI [6] and can result from procedural complications
such as distal embolization, side-branch occlusion, coronary dissec-
tion, and disruption of collateral ﬂow. Guidelines for the universal
diagnosis of MI  recommend that elevation of cardiac biomarkers to
more than three times the 99th centile of the upper reference limit
is deﬁned as a PCI-related MI  (MI  type 4a) [7].
The clinical signiﬁcance and long-term prognostic impact of PMI
were disputed initially. Early, small studies with short follow-up
found no increased risk [8], but subsequent large prospective trials
have proved that elevation of myocardial necrosis markers after
PCI are clinically relevant [9–13]. More recent studies have sug-
gested that the degree of subsequent risk correlates with the extent
of rise in troponin, CK, or CK-MB [14–16], and imaging studies
have demonstrated that post-procedural levels of troponin I repre-
sent new, irreversible myocardial injury on delayed-enhancement
magnetic resonance imaging [17]. Thus, it is generally agreed that
the rate of early and late clinical events is increased when post-
procedural enzyme release reaches levels consistent with MI  type
4a.
Stenting of coronary lesions sometimes involves the coverage
of relatively large side branches located near the target lesion. In
such cases, there is a risk of side branch compromise or occlu-
sion (stent jail) after PCI, and PMI  may  occur. The rate of side
branch compromise or occlusion has been reported to be 3–26%
Table 4
Clinical outcomes.
N (90) Nicorandil (N = 41) Control (N = 40) p value
In-hospital outcomes
Death  0 0 –
TLR 1 (2.4%) 0 0.272
STEMI 1 (2.4%) 0 0.272
CVA 1 (2.4%) 0 0.272
6 month follow-up outcomes
Death  0 0 NS
TLR 0 0 NS
STEMI 0 0 NS
CVA 0 0 NS
TLR, target lesion revasculariztion; STEMI, ST segment elevation myocardial infarc-
tion; CVA, cerebrovascular accident.
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18,19]. The mechanism has not been conﬁrmed; however, several
auses have been suggested such as coronary spasm, thrombus for-
ation, atheromatous plaque thromboembolism, dissection, and
now-plow effects [20–22].
Nicorandil, a potassium channel opener inﬂuencing both ATP-
nd nitrate-sensitive channels, has vasodilatory effects, increases
oronary blood ﬂow particularly in small vessels, improves
icrovascular circulation, prevents vasospasm, reduces cardiac
ympathetic nerve activity, reduces inﬂammation, and thereby pre-
ents slow ﬂow in patients with ischemic heart disease [23–27].
hrough its ATP-sensitive potassium channel opening function,
icorandil is thought to reduce calcium inﬂux into myocytes and to
imit membrane depolarization, and consequently to attenuate ATP
onsumption during ischemia [28]. Nicorandil would therefore be
xpected to attenuate the minor cardiac necrosis associated with
oronary stenting, resulting in reduction of cardiac enzyme release.
or these reasons, nicorandil is now used as a pharmacological
djunct to PCI. Murakami et al. revealed that intravenous 6-hour
icorandil infusion (a dose of 2 g/kg/min starting just before PCI)
educed the incidence of minor cardiac enzymes elevation in 192
atients undergoing PCI [5,29,30].
In our study, we hypothesized that intracoronary nicorandil
reatment would reduce the incidence of PMI  in angina patients
ecause it reduces cardiac necrosis, microvascular spasm of side
ranches, and local inﬂammation of the coronary artery, and
mproves microvascular circulation. We  selected stable and unsta-
le angina patients with normal baseline cardiac enzyme levels to
void confusion between MI  and PMI. We  also selected patients
ith PCI of LAD artery lesions, because LAD artery lesions have
any small side branches and a high incidence of PMI  would
e expected. However, intracoronary nicorandil administration
nduced no signiﬁcant differences in the levels of peak cardiac
nzymes after stent implantation, and did not reduce the side
ranch occlusion and PMI  rates. This lack of effect of intracoronary
icorandil administration on PMI  differs from the previous results
btained with intravenous nicorandil administration [5].
There  are several points to be considered. First, the intra-
oronary nicorandil administration method might not have been
ptimal in this study. This might also relate to the short half-life of
icorandil in the arteries; intracoronary nicorandil administration
isappears after a few minutes, but an intravenous 6-hour nico-
andil infusion has prolonged effects on the myocardium. Second,
he dose and frequency of intracoronary nicorandil administration
ight be not adequate. Larger doses of several times the amount
sed in our study could be effective on PMI. However, the safety of
arge, multiple doses of intracoronary nicorandil is not proven.
One  limitation of our study was the small sample of patients
tudied. In addition, the results do not include a quantitative analy-
is of heart function, because parameters such as echocardiography,
ardiac magnetic resonance imaging, or thallium single-photon
mission computed tomography were not examined in the study.
onclusion
Intracoronary  nicorandil administration induced no signiﬁcant
ifferences in the levels of peak cardiac enzymes after stent implan-
ation, and did not reduce the side branch occlusion and PMI  rates.
ntra-coronary nicorandil had no signiﬁcant effect on PMI  and car-
iac enzymes after PCI in patients with stable or unstable angina.cknowledgment
This  study was supported by a grant of the Korean Heath Tech-
ology R&D Project, Ministry of Health and Welfare, Republic of
orea (A070001).
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